Panel of 48 CSF proteins complements existing Alzheimer’s biomarkers
Sep 07, 2023
The CSF 48 panel plus existing biomarkers significantly improved the diagnostic performance for the outcomes studied.
Study looks at links between anxiety disorders, benzodiazepines, dementia
Aug 14, 2023
Benzodiazepines and anxiety disorders were linked to dementia risk, but no additional risk was seen for benzodiazepines in patients with anxiety disorders.
Symptoms, negative life impact seen during, after benzodiazepine use
Aug 08, 2023
The authors dub the term benzodiazepine-induced neurological dysfunction to describe neurological complications.
MIND diet plus caloric restriction no better for cognition
Jul 19, 2023
A small improvement seen in global cognition scores, but it was no different from those following control diet with mild caloric restriction.
Solanezumab does not slow cognitive decline in preclinical Alzheimer’s disease
Jul 19, 2023
The mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab or placebo.
FDA gives full approval to Alzheimer’s disease drug Leqembi
Jul 06, 2023
Although Leqembi did help reduce mental decline compared with placebo, the drug has been linked to two deaths from brain bleeds.
Incident MI tied to faster declines in cognitive function over time
Jun 05, 2023
Incident myocardial infarction is not associated with a decrease in global cognition, memory or executive function but is associated with faster declines in those measures over time.
Medicare spending would increase $2.0 to $5.1 billion with lecanemab
May 18, 2023
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636
Vestibular dysfunction may be modifiable risk factor for cognitive decline
May 08, 2023
The findings were seen in a study of people living with Meniere disease.
Stages of objective memory impairment system predicts cognitive impairment
Apr 21, 2023
There was almost a twofold higher risk for clinical progression that was seen for SOMI-1 and SOMI-2, and a nearly threefold higher risk was seen for SOMI-3/4.